HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION INDUCES BOTH POLYCLONAL AND VIRUS-SPECIFIC B-CELL ACTIVATION

被引:185
作者
SHIRAI, A
COSENTINO, M
LEITMANKLINMAN, SF
KLINMAN, DM
机构
[1] US FDA,CTR BIOL,DIV VIROL,RETROVIRUS RES LAB,BETHESDA,MD 20014
[2] NIH,DEPT TRANSFUS MED,APHORESIS SECT,BETHESDA,MD 20892
关键词
HIV; AIDS; B-CELLS; POLYCLONAL ACTIVATION; GP-160;
D O I
10.1172/JCI115621
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peripheral blood lymphocytes (PBL) were obtained from HIV-1-infected patients at different stages of disease. The absolute number of IgM-, IgG-, and IgA-producing lymphocytes per 10(6) PBL was increased 2.8-, 3.4-, and 1.9-fold, respectively, compared with normal controls. 2-17% of IgG-secreting patient cells reacted with the gp160 envelope glycoprotein of HIV-1 (a 737-fold increase over background), while 1-9% reacted with p24 (140-fold over background). In addition to this HIV-specific B cell activation, the number of lymphocytes reactive with nonviral antigens such as DNA, myosin, actin, trinitrophenylated keyhole limpet hemocyanin, and ovalbumin was increased by a mean of 17.9-fold. Evidence suggests that the latter changes reflect an HIV-induced polyclonal B cell activation unrelated to the production of anti-HIV antibodies. For example, the proportion of IgG anti-gp160- and anti-p24-secreting lymphocytes declined in patients with advanced disease, whereas the number of B cells producing antibodies to non-HIV antigens rose. Moreover, CD4 cell count and T4/T8 ratio showed a significant inverse correlation with the degree of polyclonal activation but not with anti-HIV responsiveness. These observations demonstrate that both quantitative and qualitative changes in B cell activation accompany (and may be predictive of) disease progression in HIV-infected individuals.
引用
收藏
页码:561 / 566
页数:6
相关论文
共 69 条
[1]   MAJOR GLYCOPROTEIN ANTIGENS THAT INDUCE ANTIBODIES IN AIDS PATIENTS ARE ENCODED BY HTLV-III [J].
ALLAN, JS ;
COLIGAN, JE ;
BARIN, F ;
MCLANE, MF ;
SODROSKI, JG ;
ROSEN, CA ;
HASELTINE, WA ;
LEE, TH ;
ESSEX, M .
SCIENCE, 1985, 228 (4703) :1091-1094
[2]  
AMADORI A, 1988, LANCET, V1, P852
[3]  
AMADORI A, 1989, J IMMUNOL, V143, P2146
[4]   B-CELL ACTIVATION AND HIV-1 INFECTION - DEEDS AND MISDEEDS [J].
AMADORI, A ;
CHIECOBIANCHI, L .
IMMUNOLOGY TODAY, 1990, 11 (10) :374-379
[5]   SPONTANEOUS INVITRO PRODUCTION OF VIRUS-SPECIFIC ANTIBODY BY LYMPHOCYTES FROM HIV-INFECTED SUBJECTS [J].
AMADORI, A ;
DEROSSI, A ;
FAULKNERVALLE, GP ;
CHIECOBIANCHI, L .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1988, 46 (03) :342-351
[6]  
AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447
[7]   DETECTION OF NATIVE AND DENATURED DNA ANTIBODY-FORMING-CELLS BY THE ENZYME-LINKED IMMUNOSPOT ASSAY - A CLINICAL-STUDY OF (NEW-ZEALAND BLACK X NEW-ZEALAND WHITE)F1 MICE [J].
ANDO, DG ;
EBLING, FM ;
HAHN, BH .
ARTHRITIS AND RHEUMATISM, 1986, 29 (09) :1139-1146
[8]   VIRUS ENVELOPE PROTEIN OF HTLV-III REPRESENTS MAJOR TARGET ANTIGEN FOR ANTIBODIES IN AIDS PATIENTS [J].
BARIN, F ;
MCLANE, MF ;
ALLAN, JS ;
LEE, TH ;
GROOPMAN, JE ;
ESSEX, M .
SCIENCE, 1985, 228 (4703) :1094-1096
[9]  
BRUNVEZINET F, 1984, LANCET, P1253
[10]   LOCALIZATION OF B-CELL STIMULATORY ACTIVITY OF HIV-1 TO THE CARBOXYL TERMINUS OF GP41 [J].
CHIRMULE, N ;
KALYANARAMAN, VS ;
SAXINGER, C ;
WONGSTAAL, F ;
GHRAYEB, J ;
PAHWA, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (03) :299-305